About us


For SMEs:

Get funding for innovation partnerships to digitalize biopharmaceutical R&D

Advancing precision medicine in the digital age requires solutions developed in the IT and software sector, e.g. big data, machine learning, IT security, data protection, and cross-enterprise collaboration. The PERMIDES project aims at bringing together SMEs from the biopharmaceutical and IT sector to advance precision medicine through the development of novel digital solutions along the biopharmaceutical value chain. SMEs participating in the PERMIDES project can increase competitiveness and benefit from an innovation voucher scheme that will provide up to EUR 60,000 per project. About 90 innovation projects will be supported by the voucher scheme.

How can you as a SME benefit?

SMEs from the biopharmaceutical sector get access to relevant partners from the IT sector. The IT companies can develop and implement tailored digital solutions to improve business and product development processes. The costs incurred for this purpose by the IT partner will be covered by means of consulting, prototyping and customised solution vouchers totalling up to EUR 60,000. The biopharmaceutical company may also benefit from new products and applications developed by the IT company within the framework of the joint project. SMEs from the IT sector get access to partners and new customers from the biopharmaceutical sector to apply and adapt their solutions to SMEs developing novel personalized medicine products. Innovation vouchers will cover their expenses, and the knowledge gained during these projects may create new products and business opportunities.

Which dates are important?

Winter 2016/17
Workshops in each country
  • Oslo: Workshop, December 6th
  • Vienna: Workshop, December 15th
  • Mainz: Workshop, January 16th
Spring 2017
Calls for Innovation Projects published, max. 3-month review time, open calls until spring 2018. Matchmaking events and PERMIDES Platform for partner identification will be offered from spring 2017 onwards.
Summer 2017
First innovation voucher funding granted

How is the project funded?

The PERMIDES consortium was awarded EUR 4.8 million from the EU’s Horizon2020 programme. 75% of the total amount, i.e. EUR 3.7 million, will directly benefit SMEs, with EUR 3 million to be handed out via innovation vouchers.

Who is driving the project?

Six clusters from three countries and two industrial IT partners form the PERMIDES consortium. The partners will work closely with the SMEs from their clusters to maximize the impact for the SMEs.
  • Software-Cluster c/o CyberForum e.V. (Coordinator) (DE)
  • Cluster für Individualisierte ImmunIntervention (DE)
  • Oslo Cancer Cluster S.A (NO)
  • NCE Smart Energy Markets (c/o Smart Innovation Østfold AS) (NO)
  • Oncotyrol, Center for Personalized Cancer Medicine GmbH (AT)
  • IT-Cluster - Business Upper Austria, OÖ Wirtschaftsagentur GmbH (AT)
  • intelligent views GmbH (DE)
  • NETSYNO Software GmbH (DE)

PERMIDES Strategy Document

This document outlines the strategic focus of the PERMIDES voucher based funding system and the rational for developing the matchmaking platform based on the results of a series of European workshops involving biopharmaceutical and IT SMEs during the initial PERMIDES project phase.

Download: PERMIDES Strategy Document

Core values and goals of the project

Support biopharma SMEs

The overarching objective of the PERMIDES project is to support biopharma SMEs in the field of Personalised Medicine to overcome innovation barriers and reconfigure their value chain by linking with IT SMEs and implementing cutting-edge software solutions.


Innovation Voucher Framework

Building a need-based Innovation Voucher Framework that has the potential to fulfil the objectives of this project

Five value chain challenges

Five challenges spanning the entire value chain had been identified, where innovation in Personalised Medicine could be fostered through cooperation with the IT sector.

About the PERMIDES platform

We design and implement an online portal (the PERMIDES platform) where the SMEs of the participating clusters can respond to the PERMIDES call, share their innovation ideas, and find partners. Biopharma SMEs can share project ideas and their needs for an IT solution to a specific innovation problem. IT organisations capable of delivering a solution may be identified via the PERMIDES platform using semantic searches among registered profiles. Similarly, registered IT organisations can peruse the profiles of biopharma organisations in order to identify novel opportunities for collaboration.

At the core of the PERMIDES platform lies a semantic data model, which will be developed by Intelligent Views based on input collected from relevant stakeholders at the “Pilot”- and European Workshops.Ralph Herold, i-views

The PERMIDES platform itself will be developed by NETSYNO GmbH an expert for intuitive, barrier-free Internet-based software solutions.

Potential partners may be contacted and invited to meet at a matchmaking event hosted by the consortium. Alternatively, discussions may be initiated immediately, at the discretion of the individual SMEs. The overall objective of the PERMIDES platform is to nurture interactions between the IT and biopharma sectors, forging new innovation partnerships, and spurring new initiatives addressing barriers in the Personalised Medicine value chain.


Project Facts
Project Acronym: PERMIDES

Project Title: Personsalised Medicine Innovation through Digital Enterprise Solutions

Project Reference: H2020-INNOSUP-1-2015, Grant agreement no: 691546

Project Type: Cluster facilitated projects for new value chains

Project Duration: 24 months from 01.09.2016 – 31.08.2018

Budget: € 4.838.318 (EC Funding)